{
    "clinical_study": {
        "@rank": "21598", 
        "arm_group": [
            {
                "arm_group_label": "ProTectis", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Gastrus", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Recent studies have shown an increased gastrointestinal reactivity and increased intestinal\n      permeability in IgA nephropathy (IgAN). Probiotic supplementation is known to impact the\n      gastrointestinal immune system possibly by improvement of both the immunologic and the\n      non-immunologic intestinal barrier. Probiotic supplementation should thus theoretically have\n      an effect on IgAN. In this study the investigators will study the efficacy and safety of\n      Lactobacillus reuteri."
        }, 
        "brief_title": "Probiotics in IgA Nephropathy", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "IgA Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis, IGA", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Above 18 years\n\n          -  Primary IgAN, verified by biopsy\n\n          -  Albuminuria > 0.75 g/24 h (verified by at least four sample results within a two\n             years period prior to inclusion)\n\n          -  Serum creatinine less than 200 umol/L (verified by at least four sample results\n             within a two years period prior to inclusion)\n\n          -  Having signed informed consent form\n\n        Exclusion Criteria:\n\n          -  Participation in another clinical intervention trial\n\n          -  Patients with celiac disease\n\n          -  Patients with secondary IgAN\n\n          -  Creatinine clearance below 30 ml/min (mean of 3 measurements)\n\n          -  Introduction of an ACE inhibitor or angiotensin II receptor blocker during the last\n             three months prior to inclusion\n\n          -  Patients treated with immunosuppressive or systemic corticosteroid drugs within the\n             last twelve months\n\n          -  Patients using probiotic products within the last three months (includes probiotic\n             milk products)\n\n          -  Known allergy or intolerance to any of the ingredients in the probiotic product"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781312", 
            "org_study_id": "SMR-2712", 
            "secondary_id": "SMR-2712"
        }, 
        "intervention": [
            {
                "arm_group_label": "ProTectis", 
                "intervention_name": "ProTectis", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Gastrus", 
                "intervention_name": "Gastrus", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 29, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Anders Fernstr\u00f6m, MD PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Link\u00f6ping", 
                        "country": "Sweden"
                    }, 
                    "name": "Link\u00f6ping University Hospital"
                }, 
                "investigator": {
                    "last_name": "Anders Fernstr\u00f6m, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sigrid Lundberg, MD PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "Karolinska University Hospital"
                }, 
                "investigator": {
                    "last_name": "Sigrid Lundberg, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bengt Fellstr\u00f6m, MD PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Uppsala", 
                        "country": "Sweden"
                    }, 
                    "name": "Uppsala University Hosptial"
                }, 
                "investigator": {
                    "last_name": "Bengt Fellstr\u00f6m, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Proof-of-concept Study of Efficacy and Safety of Dietary Supplementation With Probiotics in IgAN Patients", 
        "other_outcome": {
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "3 months and 5 months"
        }, 
        "overall_contact": {
            "email": "bengt.fellstrom@medsci.uu.se", 
            "last_name": "Bengt Fellstr\u00f6m, MD PhD"
        }, 
        "overall_contact_backup": {
            "email": "hilde.smerud@medsci.uu.se", 
            "last_name": "Hilde K Smerud, PhD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Regional Ethical Review Board", 
                "Sweden: Swedish Data Inspection Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in albuminuria", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781312"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Uppsala University Hospital", 
            "investigator_full_name": "Hilde Kloster Smerud", 
            "investigator_title": "Clinical Research Scientist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in renal function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }, 
            {
                "measure": "Change in IgA/IgG immune complexes", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }, 
            {
                "measure": "Change in hematuria", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }, 
            {
                "measure": "Change in immunological markers in blood", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }, 
            {
                "measure": "Change in IBS (irritable bowel syndrome) symptoms", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }
        ], 
        "source": "Uppsala University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University Hospital, Linkoeping", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Karolinska Institutet", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Uppsala University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}